bit.bio and BlueRock Therapeutics announce collaboration to advance T cell (Treg) based therapies

Tregs play a crucial role in maintaining balance in the body’s immune system and iPSC-derived Treg based therapies have the potential to treat a broad range of autoimmune and inflammatory disorders.

bit.bio will use its machine learning powered discovery platform to identify transcription factor (TF) combinations for reprogramming iPSCs into Tregs. The agreement also includes options for BlueRock to licence bit.bio’s opti-ox precision cell programming technology to control the expression of TF combinations within Treg cell therapies